Press Journals

Candidiasis Therapeutics Pipeline to Witness Many Technological Advancements in the Coming Years

May 2017

According to a new research report “Candidiasis Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Candidiasis currently exhibits a pipeline with 22 drug candidates.

As per the findings of the research, most of the candidiasis drug candidates are being developed to be administered by oral route.

Cochleate technology platform for Candidiasis drug development

Matinas Biopharma Holdings, Inc. is using Cochleate technology platform for the development of their drug candidates. The technology platform is a lipid-crystal nano-particle targeted drug delivery system, that offers a drug delivery solution with differentiating and disruptive features including oral availability, multi-organ protection, enhanced safety and targeted delivery to the site of the infection and inflammation along with the ability to effectively penetrate the tissues.

Ample Designations from the U.S. Food and Drug Administration (USFDA) to the market players manufacturing drugs for Candidiasis

The research found that various companies received many designations from the U.S. Food and Drug Administration (USFDA) for the development of candidiasis therapeutics pipeline. In May 2016, USFDA granted the orphan drug designation to SCY-078 for the treatment of invasive candida infections, including candidemia.

Some of the key players developing drugs for the treatment of candidiasis include Seren Pharmaceuticals, Inc., SCYNEXIS, Inc., Matinas Biopharma Holdings, Inc., and others.